



NEWS RELEASE

Ocumetics Announces Appointment of Michael L. Edwards to Board of Directors

For Immediate Release

Calgary, Alberta – March 11, 2025. Ocumetics Technology Corp. (“**Ocumetics**” or the “**Corporation**”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has appointed Michael Edwards, BBA, CPA, CA, CLU, to its Board of Directors.

“We are thrilled to have Michael join our board of directors,” says Dr. Garth Webb, founder and Chairman of Ocumetics. “Michael has an extensive background in accounting, taxation, corporate governance and fundraising in Canada,” adds Dr. Webb. “This experience will be invaluable as we navigate the next phase of our growth.”

Michael graduated from Acadia University with a Bachelor of Business Administration and thereafter obtained his C.A. designation, achieving the highest provincial standing (PEI) on the Uniform Final Exams. Michael spent several years working for public accounting firms in increasing areas of responsibility, and completed the CICA In-Depth Tax Course.

Michael was previously the Canadian Tax Manager for Michelin Tires Canada Ltd. and the Vice President, Finance for a regional residential/commercial real estate development company before returning to public accounting practice.

Thereafter, he became a licensed life agent, obtained the Chartered Life Underwriter “CLU” designation, and currently holds a life brokers contract for several major life companies through Customized Insurance & Tax Solutions Inc.

Currently, Michael is insurance life licensed and a registered Dealing Representative of Pinnacle Wealth Brokers Ltd., an exempt market dealer registered in most provinces. Michael specializes in insurance and exempt market investment products and is President and Director of EDC Tax Services Inc.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetix is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetix has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns
President and CEO
(817) 874-7564

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.